Kelt - Pfizer owns sunitinib. In January, CTIX pr'd DF (BIDMC) research showing sunitinib in combo with Kevetrin showed in vivo renal tumor shrinkage. So that is not new news.

I am most confused about the sample issue. Dana Farber - with it's New England network - never has to do much advertising work when it runs a new molecule trial. So they should have enough participants.. They also must stick to the protocol they wrote for their trial. Cohort expansion is allowed for clarification of mtd. That's it. (unless they asked for a protocol change which we would probably know about and which would cause a much longer delay given need for IRB approval of new protocol). So...what's up with need for more samples? Did they have some unexpected trouble recruiting? It's befuddling.